Insights^

Medicare Advantage (MA) plans have become increasingly popular in recent years, offering seniors and those with disabilities an alternative to traditional Fee-For-Service (FFS) Medicare by providing additional benefits such as vision, dental, and wellness programs. As the program’s popularity grows, its future is becoming a critical issue in the health care policy arena. The upcoming finalization of the 2026 MA rule by the Trump Administration underscores the timeliness of this discussion. Furthermore, remarks from Republican leaders, including support from figures like Centers for Medicare and Medicaid Services (CMS) Administrator nominee Dr. Mehmet Oz, have floated the possibility of expanding the program. However, while expansion may seem attractive, there are significant practical and political challenges that must be addressed to succeed.  

Practical Challenges 

Although MA plans offer appealing benefits, their expansion presents several practical hurdles. These challenges raise concerns across the political spectrum and could complicate efforts to broaden the program’s reach. 

Provider Network Limitations 

One key issue is the restriction of provider networks within MA plans. Critics argue that these limitations can jeopardize seniors’ access to their preferred doctors or hospitals, particularly in rural areas with limited provider options. Ensuring that concerns about network adequacy are addressed will be critical for any attempts to expand MA. 

Complexity in Choosing Plans 

The rapid proliferation of MA options has introduced another challenge: choice overload. With so many plans available, it can be challenging for seniors to navigate their options and fully understand what each plan offers. Lawmakers and stakeholders have voiced concerns about whether beneficiaries have the necessary information to make informed decisions. Expanding the MA program could compound this challenge.  

Cost Concerns 

Expanding MA could place additional strain on federal budgets. In its 2024 MA status report to Congress, the Medicare Payment Advisory Commission (MedPAC) estimated that MA plans would receive $83 billion more in payments than traditional Medicare. Program critics could resist proposals for expansion unless it’s clear how costs will be managed without sacrificing the quality or scope of coverage. 

Prior Authorization Reform 

Another practical challenge is prior authorization requirements within MA plans. Republicans and Democrats have criticized these requirements for leading to improper coverage denials and delaying or denying beneficiaries access to necessary care. The bipartisan interest in prior authorization reform—evidenced by widespread support for related legislation in the last Congress—will likely need to be addressed before any meaningful expansion can proceed. 

Political Challenges 

The practical challenges of expanding MA also translate into political obstacles, which could hinder further efforts to grow the program. 

Resistance from Seniors 

Some seniors, a key voting bloc, may resist changes to MA, particularly if they perceive reforms as threatening their access to care. Concerns about limited networks and burdensome prior authorization requirements have already drawn criticism. These issues and lingering memories of political fallout from previous health care reform efforts (such as the Affordable Care Act’s repeal-and-replace saga) may bring political risks for those who want to expand the program.  

Opposition from Health Care Providers 

Some health care providers, especially those in rural areas, have voiced opposition to MA due to lower reimbursement rates and coverage limitations. Rural hospitals and providers are significant voices in rural communities, and addressing any concerns they raise will be essential to gaining political support for expansion. Without buy-in from these stakeholders, efforts to expand the program could be derailed. 

Partisan Divisions 

MA has historically aligned with conservative ideals of promoting private sector involvement in Medicare, while program skeptics, particularly among liberals, have raised concerns about the program’s cost and accessibility. Although ideological divisions on MA have softened since the program’s inception, how much Democratic support there might be for expanding MA is unclear. Given the razor-thin Republican majority in the House and the need for bipartisan support in the Senate (where filibuster rules require 60 votes for most legislation), political divisions could make passing expansion measures particularly challenging. 

Conclusion 

Expanding MA may offer potential benefits for seniors, but it also may present practical and political challenges. From concerns about provider networks and plan complexity to disagreements over costs and program oversight, these hurdles must be addressed before any expansion effort can gain traction. For those who might support expansion, crafting policies that mitigate these challenges will be key to moving forward with any proposals to grow MA. Ultimately, success will depend on balancing the needs of beneficiaries, health care providers, and political stakeholders while ensuring the program remains sustainable and accessible. 

Reforming Prior Authorization in Health Plans: A Bipartisan Issue for the 119th Congress? 

As the 119th Congress begins its legislative work, one of the issues gaining increasing attention within health care reform is prior authorization. But will this issue unite lawmakers across party lines, or will it become another partisan battleground?  

Prior Authorization: A Growing Problem 

Prior authorization is intended to ensure that medical services or treatments are medically necessary and cost-effective, helping to control health care expenses. However, over time, critics argue that prior authorization has become a cumbersome and bureaucratic obstacle that delays patient care. According to a 2024 survey by the American Medical Association (AMA), 94% of physicians report that prior authorization causes delays in patient care, with some of these delays resulting in worsened health outcomes (AMA, 2024). Moreover, health care providers are spending more time on administrative tasks related to prior authorization requests, detracting from their ability to focus on direct patient care. 

The burden of prior authorization is not confined to any one area of health care. Prior authorization affects public and private insurance systems and extends beyond medical services, including medications, imaging procedures, and durable medical equipment.  While prior authorization is used to manage costs and prevent overuse of health care  services, the process can be time-consuming and opaque, contributing to frustration for patients, providers, and insurers alike. 

A Bipartisan Issue? 

Prior authorization reform has historically garnered support from both parties, particularly as the system’s burdens have become more apparent. On the one hand, Democrats have focused on reducing administrative inefficiencies and improving access to timely care. At the same time, Republicans have typically championed efforts to cut through regulatory red tape and strengthen health care cost management. 

For instance, in the previous Congress, a bipartisan bill, The Improving Seniors’ Timely Access to Care Act, aimed to reduce the burden of prior authorization for Medicare Advantage beneficiaries by introducing requirements for transparency, quicker decision-making, and a more standardized process. The legislation received broad backing from both Democrats and Republicans (with over half of members in both bodies cosponsoring the bill), alongside support from leading medical and patient advocacy groups, including the AMA and the American Heart Association. 

As Congress moves into the 119th session, the push for reforms to the prior authorization process remains strong. However, expanding these reforms across broader health care  sectors, particularly private insurance, will require navigating complex political dynamics. While there is a shared interest in reducing administrative burdens, insurers and Republicans who prioritize cost control may resist significant changes to the system. 

Potential Pitfalls of Reform 

Despite the broad support for prior authorization reform, Congress will face several key challenges to pass meaningful legislation. 

1. Resistance from Insurance Companies: Many insurance companies view prior authorization as a necessary tool to manage costs and ensure the appropriate use of health care  services. While insurers may acknowledge the administrative burdens on providers, they often argue that eliminating or loosening prior authorization would result in unnecessary treatments, driving up health care  expenditures. This perspective could lead to significant pushback from the insurance industry, which may be able to influence lawmakers concerned about costs. 
2. Balancing Cost Control with Patient Care: One of the primary concerns of prior authorization reform is maintaining a balance between reducing administrative barriers and ensuring that only medically necessary treatments are covered. If the prior authorization process is reduced too much, there may be concerns about increased utilization of unnecessary services, which could ultimately increase the cost of health care across the board. 
3. Fragmentation Across Insurance Plans: With multiple insurance plans, both public and private, there is a lack of uniformity in the prior authorization process. Different insurers often have varying rules and guidelines, leading to confusion for both patients and health care  providers. Creating a standard process across different plans could face significant resistance from the insurance industry, which may prefer to maintain its own policies and decision-making frameworks. 

Where will the Administration Stand on the issue? 

During his previous presidency, President Trump made efforts to reduce the burden of regulatory requirements in health care, including addressing prior authorization. In 2020, his administration signed an executive order aimed at improving transparency in health care  pricing and addressing the burdens of prior authorization within both public and private health care systems. The executive order pushed for greater transparency from insurers regarding prior authorization rules and encouraged the development of electronic systems to streamline the process. 

Although President Trump has not specifically spoken about prior authorization reform since leaving office, his overall approach to health care reform—focused on reducing government regulation and enhancing competition within the health care market—suggests he may support efforts to reduce administrative burdens. However, his stance on health care policy generally favors market-driven solutions, meaning that any reform efforts might need to strike a balance between improving patient care and preserving cost-control mechanisms within the insurance industry. 

So, will Congress and the administration act on reforming prior authorization this year? While bipartisan support for reform exists, the complexities involved in balancing patient care, cost control, and insurance company interests could complicate the passage of significant legislation. As the legislative process moves forward, watching how Congress navigates these challenges will be important. However, we have seen over the past month that most citizens are angry about health insurance profit levels and perceived lack of access to care – so Congress will need to act on this issue one way or another before the end of 2025.   

The Trump Administration is poised to reshape American health care policy with two high-profile and polarizing figures: Robert F. Kennedy Jr., nominated to head the Department of Health and Human Services (HHS), and Mehmet Oz, the celebrity doctor tapped to lead the Centers for Medicare and Medicaid Services (CMS). Their starkly different approaches to health care—prevention versus medicine—set the stage for potential clashes on key issues. One such issue, Medicare coverage of Ozempic, highlights the philosophical divide between these two leaders and serves as a litmus test for the future of U.S. health care. 

Medicare and Medicaid for GLP1-s 

Ozempic, a GLP-1 receptor agonist originally developed to treat Type 2 diabetes, has rapidly gained attention for its weight-loss benefits. For many, the drug represents a breakthrough in managing obesity, a major driver of chronic diseases in the U.S.   

The Biden administration proposed to expand Medicare coverage of GLP-1s beyond its use to treat type 2 diabetes or cardiovascular disease.  If the Trump administration finalizes the rule, CMS estimates 7 percent more Americans would have access to the drug.  But Medicaid coverage remains limited, with only 13 state Medicaid programs paying for GLP-1s for obesity treatment, 

GLP-1s headline the government’s list of medicines that will be subject to price negotiations over the next year as part of the Inflation Reduction Act.  In addition to traditional Medicare, these drugs, including Ozempic, will also be subject to price negotiations,  

The Ozempic Debate: A Microcosm of Medicine vs. Prevention 

Dr. Mehmet Oz has championed the potential of Ozempic and other GLP-1s, calling the drug ‘massively beneficial’ for improving cardiovascular health and overall quality of life. He sees expanding access to drugs like Ozempic through Medicare and Medicaid as a critical step in addressing obesity and its associated costs. 

In stark contrast, RFK views Ozempic with deep skepticism. He has labeled it a ‘scam’ and insists that the true solution to obesity lies in lifestyle changes, such as eating healthier and exercising more. In interviews, he has criticized the pharmaceutical industry for profiting off what he considers preventable health issues, stating that Americans have been ‘misled’ into seeking quick fixes rather than addressing the root causes of their health problems. 

RFK ’s Prevention-First Agenda 

As head of HHS, RFK brings a prevention-focused vision to health care policy. He has long advocated for systemic reforms, including stricter regulations on processed foods, food additives, and environmental toxins. He aims to address obesity by overhauling the U.S. food system, rather than relying on pharmaceutical interventions. His skepticism extends beyond the GLP-1s to the broader role of the pharmaceutical industry, which he accuses of prioritizing profit over public health. 

RFK plans to reallocate resources within HHS, shifting the focus of agencies like the National Institutes of Health (NIH) from infectious diseases to chronic disease prevention. However, implementing such sweeping reforms will be no easy task. HHS is a massive bureaucracy, and many of his proposals—such as limiting fluoride in drinking water or promoting the value of unpasteurized or “raw” milk—also fall under the purview of other federal agencies, like EPA and CDC. Institutional inertia and budgetary constraints may further hinder his efforts. 

Dr. Oz Supports New Innovations 

Mehmet Oz’s tenure at CMS will likely emphasize medical innovation and treatment. A vocal supporter of GLP-1s like Ozempic and Wegovy, Oz views such drugs as essential tools for improving public health outcomes. He has advocated for making GLP-1 inhibitors widely accessible and believes Medicare and Medicaid coverage of these drugs would yield significant long-term health benefits. 

Oz’s enthusiasm for medical solutions extends to telehealth and digital health technologies, which he sees as critical for increasing access to care. His leadership may prioritize policies integrating these technologies into Medicare and Medicaid programs, potentially creating new avenues for managing obesity and other chronic conditions. 

The Ozempic debate is likely the first of many policy clashes between RFK Jr. and Oz. As CMS Administrator, Oz could advocate for expanding Medicare coverage of Ozempic, while RFK Jr., as head of HHS, may push back in favor of prevention-focused alternatives 

The  focus may shift toward public health campaigns promoting lifestyle changes, potentially delaying access to pharmaceutical interventions for those who need them. On the other hand, if Oz’s perspective dominates, Medicare and Medicaid could see expanded pharmaceutical coverage, but at significant financial cost and without addressing the underlying causes of obesity. 

Conclusion 

The leadership of RFK Jr. and Mehmet Oz at HHS and CMS marks a pivotal moment for American health care. The Ozempic debate encapsulates the broader philosophical divide between prevention and medicine, offering a glimpse into the challenges and opportunities that lie ahead. Whether their approaches can coexist—or whether one will prevail—remains to be seen.  

The Trump administration’s approach to Ozempic may offer a glimpse into U.S. health care policy for the next four years.  How will HHS and CMS address chronic diseases, allocate resources, and balance prevention with treatment?  How will Medicare and Medicaid navigate the institutional and budgetary constraints while pursuing transformative change? 

Moreover, the dynamic between RFK Jr. and Oz may set the tone for how the Trump Administration handles other contentious health care issues, from vaccine policies to public health emergencies. Will their contrasting visions lead to innovation and compromise, or will their differences hinder progress?